Market Overview

ICYMI: Valeant, Overstock And Biotechs

Related GRPN
32 Biggest Movers From Yesterday
28 Stocks Moving In Monday's Mid-Day Session
Related REGN
A Peek Into The Markets: U.S. Stock Futures Down; NASDAQ Futures Tumble Over 2%
Strong Trial Results, Effective Distribution Could Put Regeneron's Praluent 'Back In The Competition'
Your Daily Pharma Scoop: Omeros' Omidria, Titan Signs Agreement, Reata Announces Top-Line Results (Seeking Alpha)

In case you missed it, here are some of Benzinga's top stories from Monday, March 5, 2018.

A Valeant Bear Relents

Learn what finally convinced Deutsche Bank’s Gregg Gilbert to grant a buy rating to Valeant Pharmaceuticals Inc (NYSE: VRX) in Elizabeth Balboa’s “How Valeant Finally Won Over A Longtime Bear.”

Overstock Bull Sharpens His Horns Ahead Of ICO

Despite last week’s SEC scare, Inc (NASDAQ: OSTK) is still a hot stock with plenty of upside, according to D.A. Davidson. Get some background on this bull’s thesis in Wayne Duggan’s “Analyst Stays Bullish On Overstock's tZERO Coin Offering Despite Regulatory Risk.”

Related Link: Morgan Stanley Says Groupon's 16% Decline In 2018 Is 'Overdone'

Keep Your Eyes Peeled For These 7 Biotechs In March

From Regeneron Pharmaceuticals Inc (NASDAQ: REGN) to ImmunoGen, Inc (NASDAQ: IMGN), several biotechs are expected to release meaningful updates on their clinical programs this month. Shanthi Rexaline has the details.

Latest Ratings for GRPN

Mar 2018Morgan StanleyUpgradesUnderweightEqual-Weight
Feb 2018JP MorganMaintainsNeutralNeutral
Jan 2018Goldman SachsUpgradesSellNeutral

View More Analyst Ratings for GRPN
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Cryptocurrency News Previews After-Hours Center Markets Analyst Ratings


Related Articles (IMGN + GRPN)

View Comments and Join the Discussion!